Cibinqo Approved for Adolescents With Moderate to Severe Atopic Dermatitis
The approval was based on data from previous studies that included 124 adolescent patients, as well as the phase 3 JADE TEEN study.
Diagnosis & Disease Information
Tapinarof Cream Eases Atopic Dermatitis in Patients as Young as 2 Years
Results showed a significantly greater proportion of patients treated with tapinarof cream achieved vIGA-AD success compared with vehicle cream.
Mode of Delivery May Be a Risk Factor for Early Childhood Atopic Dermatitis
A cohort study of mother and child pairs investigates the association between mode of delivery and atopic dermatitis in children 5 years of age and younger.
Consistent Results Observed With Topical Roflumilast in Second Atopic Dermatitis Trial
The INTEGUMENT-2 trial included patients 6 years of age and older with mild to moderate atopic dermatitis involving at least 3% body surface area.
OTC Moisturizers Are Cost-Effective Treatment for Atopic Dermatitis
Theoretical annual costs of OTC moisturizer are compared with costs of atopic dermatitis; Medicaid coverage is also reviewed.
AAD Releases Guideline to Increase Awareness on Comorbidities in Atopic Dermatitis
A new American Academy of Dermatology (AAD) guideline describes available evidence on comorbidities associated with atopic dermatitis (AD) in adults.
Dupixent Approved for Atopic Dermatitis in Younger Pediatric Patients
The approval was based on data from a phase 3 study that evaluated Dupixent added to low potency topical corticosteroids in children aged 6 months to 5 years with uncontrolled moderate to severe atopic dermatitis.
Lebrikizumab-Associated Improvements in Skin Clearance Maintained in Atopic Dermatitis Trials
The ADvocate 1 and ADvocate 2 trials evaluated lebrikizumab as monotherapy in patients aged 12 years and older weighing at least 40kg with moderate to severe atopic dermatitis.
Protective Effect of Atopic Dermatitis on Serum Lipid Levels
The relationship between atopic disease and serum lipid levels is investigated.
Dupilumab Under Review for Atopic Dermatitis in Children Aged 5 Years and Younger
The sBLA is supported by data from the phase 3 LIBERTY AD PRESCHOOL study.
- Loading...
Loading...
Next post in Pediatrics
Loading... 
Loading...